Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 7;5(3):ofy031.
doi: 10.1093/ofid/ofy031. eCollection 2018 Mar.

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value

Natalia Olchanski  1 , Ryan N Hansen  2 , Elle Pope  1 , Brittany D'Cruz  1 , Jaime Fergie  3 , Mitchell Goldstein  4 , Leonard R Krilov  5 , Kimmie K McLaurin  6 , Barbara Nabrit-Stephens  7 , Gerald Oster  8 , Kenneth Schaecher  9 , Fadia T Shaya  10 , Peter J Neumann  1 , Sean D Sullivan  2
Affiliations
Review

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value

Natalia Olchanski et al. Open Forum Infect Dis. .

Abstract

Respiratory syncytial virus (RSV) infection is the most common cause of lower respiratory tract infection and the leading cause of hospitalization among young children, incurring high annual costs among US children under the age of 5 years. Palivizumab has been found to be effective in reducing hospitalization and preventing serious lower respiratory tract infections in high-risk infants. This paper presents a systematic review of the cost-effectiveness studies of palivizumab and describes the main highlights of a round table discussion with clinical, payer, economic, research method, and other experts. The objectives of the discussion were to (1) review the current state of clinical, epidemiology, and economic data related to severe RSV disease; (2) review new cost-effectiveness estimates of RSV immunoprophylaxis in US preterm infants, including a review of the field's areas of agreement and disagreement; and (3) identify needs for further research.

Keywords: cost-effectiveness; expert review; immunoprophylaxis; pediatrics; respiratory syncytial virus; value.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Literature search and selection flow diagram.
See this image and copyright information in PMC

References

    1. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002; 21:629–32. - PubMed
    1. Doucette A, Jiang X, Fryzek J et al. . Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States Nationally Representative Database, 1997-2012. PLoS One 2016; 11:e0152208. - PMC - PubMed
    1. Hall CB, Weinberg GA, Iwane MK et al. . The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588–98. - PMC - PubMed
    1. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004; 22:275–84. - PubMed
    1. Haynes AK, Prill MM, Iwane MK, Gerber SI; Centers for Disease Control and Prevention (CDC) Respiratory syncytial virus–United States, July 2012-June 2014. MMWR Morb Mortal Wkly Rep 2014; 63:1133–6. - PMC - PubMed